Federal Register / Vol. 87, No. 20 / Monday, January 31, 2022 / Notices 4887 

From there, access the linked 

‘‘Instructions for board meeting 

visitors.’’ 

STATUS: This meeting will be open to the 

public. 

MATTERS TO BE CONSIDERED: 

• Approval of January 13, 2022 Minutes 

• Report on the Young, Beginning, and 

Small Farmers and Ranchers Forum 

• Report on Farm Input Prices 

• Conservators and Receivers Proposed 

Rule 

CONTACT PERSON FOR MORE INFORMATION: 

If you need more information, need 

assistance for accessibility reasons, or 

have questions, contact Ashley 

Waldron, Secretary to the Board. 

Telephone: 703–883–4009. TTY: 703– 

883–4056. 

Ashley Waldron, 

Secretary to the Board. 

[FR Doc. 2022–02058 Filed 1–27–22; 4:15 pm] 

BILLING CODE 6705–01–P 

FEDERAL COMMUNICATIONS 

COMMISSION 

Federal Advisory Committee Act; 

Technological Advisory Council 

AGENCY: Federal Communications 

Commission. 

ACTION: Notice of public meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, this 

notice advises interested persons that 

the Federal Communications 

Commission’s (FCC) Technological 

Advisory Council will hold a meeting. 

In addition, a full list of the TAC 

membership is attached to the Public 

Notice. 

DATES: Monday, February 28, 2022, 

starting at 10:00 a.m., via video 

conference and will be available to the 

public via the internet. 

ADDRESSES: Federal Communications 

Commission, 45 L Street NE, 

Washington, DC 20554. 

FOR FURTHER INFORMATION CONTACT: 

Michael Ha, Chief, Policy and Rules 

Division, 202–418–2099; Michael.Ha@

FCC.gov. 

SUPPLEMENTARY INFORMATION: This is the 

first meeting of the Technological 

Advisory Council for 2022. This serves 

as Notice that, consistent with the 

Federal Advisory Committee Act, 

Federal Communications Commission 

(FCC or Commission) Chairwoman 

Jessica Rosenworcel has appointed 

members to serve on the Technological 

Advisory Council (TAC). 

A full list of the TAC membership is 

attached to the Public Notice, DA 22–56, 

released January 19, 2022, https://

www.fcc.gov/document/fcc-announcesmembership-and-first-meeting-tac. The 

TAC, comprised of a diverse group of 

leading technology experts, provides 

technical expertise to the Commission 

to identify important areas of innovation 

and develop informed technology 

policies supporting the United States’ 

competitiveness in the global economy. 

The TAC will consider and advise the 

Commission on topics such as 6G, 

artificial intelligence, advanced 

spectrum sharing technologies, and 

emerging wireless technologies, 

including new tools to restore internet 

access during shutdowns and other 

disruptions. 

Meetings are broadcast live with open 

captioning over the internet from the 

FCC Live web page at http://

www.fcc.gov/live/. The public may 

submit written comments before the 

meeting to: Michael Ha, the FCC’s 

Designated Federal Officer for 

Technological Advisory Council by 

email: Michael.Ha@fcc.gov or U.S. 

Postal Service Mail (Michael Ha, 

Federal Communications Commission, 

Room 2–A665, 45 L Street NE, 

Washington, DC 20554). Open 

captioning will be provided for this 

event. Other reasonable 

accommodations for people with 

disabilities are available upon request. 

Requests for such accommodations 

should be submitted via email to 

fcc504@fcc.gov or by calling the Office 

of Engineering and Technology at (202) 

418–2470 (voice), (202) 418–1944 (fax). 

Such requests should include a detailed 

description of the accommodation 

needed. In addition, please include your 

contact information. Please allow at 

least five days advance notice; last 

minute requests will be accepted, but 

may be impossible to fill. 

Federal Communications Commission. 

Ronald T. Repasi, 

Acting Chief, Office of Engineering and 

Technology. 

[FR Doc. 2022–01919 Filed 1–28–22; 8:45 am] 

BILLING CODE 6712–01–P 

FEDERAL RESERVE SYSTEM 

Formations of, Acquisitions by, and 

Mergers of Bank Holding Companies 

The companies listed in this notice 

have applied to the Board for approval, 

pursuant to the Bank Holding Company 

Act of 1956 (12 U.S.C. 1841 et seq.) 

(BHC Act), Regulation Y (12 CFR part 

225), and all other applicable statutes 

and regulations to become a bank 

holding company and/or to acquire the 

assets or the ownership of, control of, or 

the power to vote shares of a bank or 

bank holding company and all of the 

banks and nonbanking companies 

owned by the bank holding company, 

including the companies listed below. 

The public portions of the 

applications listed below, as well as 

other related filings required by the 

Board, if any, are available for 

immediate inspection at the Federal 

Reserve Bank(s) indicated below and at 

the offices of the Board of Governors. 

This information may also be obtained 

on an expedited basis, upon request, by 

contacting the appropriate Federal 

Reserve Bank and from the Board’s 

Freedom of Information Office at 

https://www.federalreserve.gov/foia/ 

request.htm. Interested persons may 

express their views in writing on the 

standards enumerated in the BHC Act 

(12 U.S.C. 1842(c)). 

Comments regarding each of these 

applications must be received at the 

Reserve Bank indicated or the offices of 

the Board of Governors, Ann E. 

Misback, Secretary of the Board, 20th 

Street and Constitution Avenue NW, 

Washington DC 20551–0001, not later 

than March 2, 2022. 

A. Federal Reserve Bank of Dallas 

(Karen Smith, Director, Applications) 

2200 North Pearl Street, Dallas, Texas 

75201–2272: 

1. CBTX, Inc., Beaumont, Texas; to 

merge with Allegiance Bancshares, Inc., 

and thereby indirectly acquire 

Allegiance Bank, both of Houston, 

Texas. 

Board of Governors of the Federal Reserve 

System, January 26, 2022. 

Margaret McCloskey Shanks, 

Deputy Secretary of the Board. 

[FR Doc. 2022–01920 Filed 1–28–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–22–22CC; Docket No. CDC–2022– 

0010] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 


khammond on DSKJM1Z7X2PROD with NOTICES
4888 Federal Register / Vol. 87, No. 20 / Monday, January 31, 2022 / Notices 

burden and maximize the utility of 

government information, invites the 

general public and other federal 

agencies the opportunity to comment on 

a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on a 

proposed information collection project 

titled Assessment for the Be Antibiotics 

Aware Consumer and Healthcare 

Professional (HCP) Campaign. 

Individuals who have opted to be 

contacted for surveys will be screened 

for eligibility and given access to an 

online survey to assess the Be 

Antibiotics Aware campaign, which is 

designed to optimize antibiotic 

prescribing and use. 

DATES: CDC must receive written 

comments on or before April 1, 2022. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2021– 

0010 by either of the following methods: 

• Federal eRulemaking Portal: 

Regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(regulations.gov) or by U.S. mail to the 

address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; phone: 

404–639–7570; Email: omb@cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

Assessment for the Be Antibiotics 

Aware Consumer and HCP Campaign— 

New—National Center for Emerging and 

Zoonotic Infectious Diseases (NCEZID), 

Centers for Disease Control and 

Prevention (CDC). 

Background and Brief Description 

Antibiotic resistance (AR) is one of 

the most urgent threats to public health 

in the United States. Antibiotic resistant 

bacteria have grown more virulent, 

prevalent, and diverse and can spread 

between human and animals. Each year 

there are more than 2.8 million 

antibiotic-resistant infections in the 

United States and 35,000 individuals 

die as a result. At least 30 percent of 

antibiotics prescribed to outpatients and 

emergency departments are unnecessary 

which amounts to 47 million excess 

prescriptions per year. One of the main 

side effects of taking antibiotics is 

alteration of the microbiome which 

could lead to infections such as C. 

difficile, the inability to treat infections, 

prolonged illness, or even death. Risk 

factors for AR include lack of 

knowledge, sub-therapeutic doses, 

excessive use, antibiotic residues, and 

incorrect storage. In addition, there can 

be impacts on productivity, healthcare 

costs, and it can serve as a drain on the 

economy. 

The National Action Plan calls for 

federal agencies to accelerate their 

response to AR. The goals of the 

National Action Plan are to coordinate 

strategic actions in order to ‘‘improve 

the health and well-being of all 

Americans across the One Health 

Spectrum.’’ In 2015, the National Action 

Plan set off with the goal to reduce 

inappropriate outpatient antibiotic use 

by 50 percent by 2020. It prioritizes 

prevention and control to prevent 

infection and reduce the need for 

antibiotics. Their approach, One Health, 

recognizes the inter-relatedness of 

humans, animals, and the environment. 

One way to decrease the use of 

unnecessary antibiotic prescriptions is 

through antibiotic stewardship. 

The goals of the Be Antibiotics Aware 

campaign are to seek optimization of 

antibiotic prescribing and use in order 

to improve patient safety and healthcare 

quality and to combat AR by raising 

knowledge and awareness, and 

motivating behavior change among 

target consumer and HCP audiences. 

Online panel surveys will be utilized to 

recruit participants. Surveys will be 

distributed to consumer target groups 

both pre- and post-campaign. 

Consumer audiences include: 

(1) Spanish speaking women, ages 18– 

64, 

(2) Healthy adults who visit urgent 

care, ages 18–64, 

(3) Community dwelling older adults, 

ages 65+, and 

(4) Family caregivers of nursing home 

(long-term care) residents. 

HCP audiences include: 

(1) Hospitalists, 

(2) Dentists, 

(3) Community pharmacists, 

(4) Physicians and advanced practice 

providers in nursing homes, and 

(5) Nurses in nursing homes. 

This evaluation will assist CDC in 

determining if the Be Antibiotics Aware 

media campaign was successful in 

raising knowledge and awareness and 

motivating behavior change among 

target consumer and HCP audiences in 

select markets. The information 

gathered from this evaluation will also 

be used to inform refinement and 

implementation of the campaigns 

(materials and tactics). 

CDC requests OMB approval for an 

estimated 68 annual burden hours. 

There is no cost to respondents other 

than their time. 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 87, No. 20 / Monday, January 31, 2022 / Notices 4889 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response (in 

hours) 

Total burden 

(in hours) 

Consumers .................... Be Antibiotics Aware Consumer Pilot Assessment Pretest.50 1 20/60 17 

Consumers .................... Be Antibiotics Aware Consumer Pilot Assessment Posttest.50 1 20/60 17 

HCPs ............................. HCP Be Antibiotics Aware Campaign Pretest .... 50 1 20/60 17 

HCPs ............................. Be Antibiotics Aware Posttest ............................. 50 1 20/60 17 

Total ........................ .............................................................................. ........................ ........................ ........................ 68 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2022–01886 Filed 1–28–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2022–0015] 

Advisory Committee on Immunization 

Practices (ACIP) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting and request 

for comment. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC) announces the 

following meeting of the Advisory 

Committee on Immunization Practices 

(ACIP). This meeting is open to the 

public. Time will be available for public 

comment. The meeting will be webcast 

live via the World Wide Web. 

DATES: The meeting will be held on 

February 23–24, 2022, from 10:00 a.m. 

to 5:00 p.m., EST (times subject to 

change). Written comments must be 

received on or before February 24, 2022. 

ADDRESSES: You may submit comments 

identified by Docket No. CDC–2022– 

0015 by either of the following methods: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Centers for Disease Control 

and Prevention, 1600 Clifton Road NE, 

MS H24–8, Atlanta, Georgia 30329– 

4027, Attn: ACIP Meeting. 

Instructions: All submissions received 

must include the Agency name and 

Docket Number. All relevant comments 

received in conformance with the 

https://www.regulations.gov suitability 

policy will be posted without change to 

https://www.regulations.gov, including 

any personal information provided. For 

access to the docket to read background 

documents or comments received, go to 

https://www.regulations.gov. 

Written public comments submitted 

72 hours prior to the ACIP meeting will 

be provided to ACIP members before the 

meeting. 

FOR FURTHER INFORMATION CONTACT: 

Stephanie Thomas, ACIP Committee 

Management Specialist, National Center 

for Immunization and Respiratory 

Diseases, Centers for Disease Control 

and Prevention, 1600 Clifton Road NE, 

MS H24–8, Atlanta, Georgia 30329– 

4027; Telephone: (404) 639–8367; 

Email: ACIP@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The committee is charged 

with advising the Director, CDC, on the 

use of immunizing agents. In addition, 

under 42 U.S.C. 1396s, the committee is 

mandated to establish and periodically 

review and, as appropriate, revise the 

list of vaccines for administration to 

vaccine-eligible children through the 

Vaccines for Children (VFC) program, 

along with schedules regarding dosing 

interval, dosage, and contraindications 

to administration of vaccines. Further, 

under provisions of the Affordable Care 

Act, section 2713 of the Public Health 

Service Act, immunization 

recommendations of the ACIP that have 

been approved by the CDC Director and 

appear on CDC immunization schedules 

must be covered by applicable health 

plans. 

Matters To Be Considered: The agenda 

will include discussions on, hepatitis B 

vaccines, influenza vaccines, 

pneumococcal vaccine, cholera vaccine, 

human papillomavirus vaccine, MMR 

vaccine, respiratory syncytial virus 

vaccine, and tickborne encephalitis 

vaccine. Recommendation votes on 

cholera vaccine and tickborne 

encephalitis vaccine are scheduled. No 

Vaccines for Children (VFC) votes are 

scheduled. Agenda items are subject to 

change as priorities dictate. For more 

information on the meeting agenda visit 

https://www.cdc.gov/vaccines/acip/ 

meetings/meetings-info.html. 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data. Please note that comments 

received, including attachments and 

other supporting materials, are part of 

the public record and are subject to 

public disclosure. Comments will be 

posted on https://www.regulations.gov. 

Therefore, do not include any 

information in your comment or 

supporting materials that you consider 

confidential or inappropriate for public 

disclosure. If you include your name, 

contact information, or other 

information that identifies you in the 

body of your comments, that 

information will be on public display. 

CDC will review all submissions and 

may choose to redact, or withhold, 

submissions containing private or 

proprietary information such as Social 

Security numbers, medical information, 

inappropriate language, or duplicate/ 

near duplicate examples of a mass-mail 

campaign. CDC will carefully consider 

all comments submitted into the docket. 

Written Public Comment: Written 

comments must be received on or before 

February 24, 2022. 

Oral Public Comment: This meeting 

will include time for members of the 

public to make an oral comment. Oral 

public comment will occur before any 

scheduled votes including all votes 

relevant to the ACIP’s Affordable Care 

Act and Vaccines for Children Program 

roles. Priority will be given to 

individuals who submit a request to 

make an oral public comment before the 

meeting according to the procedures 

below. 

Procedure for Oral Public Comment: 

All persons interested in making an oral 

public comment at the February 23–24, 

2022, ACIP meeting must submit a 

request at http://www.cdc.gov/vaccines/ 


khammond on DSKJM1Z7X2PROD with NOTICES